These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27771532)

  • 1. Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
    Han C; Nie S; Chen G; Ma K; Xiong N; Zhang Z; Xu Y; Wang T; Papa SM; Cao X
    Neuroscience; 2017 Jan; 340():23-33. PubMed ID: 27771532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Lebel M; Chagniel L; Bureau G; Cyr M
    Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
    Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K; Tanaka T; Takahashi T; Hiramatsu N; Ota Y; Ago Y; Matsuda T
    Eur J Pharmacol; 2012 May; 683(1-3):166-73. PubMed ID: 22449381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
    Guan Q; Liu X; He Y; Jin L; Zhao L
    Int J Neurosci; 2010 Jun; 120(6):421-7. PubMed ID: 20504213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
    BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and cellular dopamine D
    Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
    Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
    Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
    Engeln M; Bastide MF; Toulmé E; Dehay B; Bourdenx M; Doudnikoff E; Li Q; Gross CE; Boué-Grabot E; Pisani A; Bezard E; Fernagut PO
    Biol Psychiatry; 2016 Mar; 79(5):354-361. PubMed ID: 25146322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
    Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
    Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
    Gomez G; Saborido MD; Bernardi MA; Gershanik OS; Taravini IR; Ferrario JE
    Neurosci Lett; 2018 Feb; 666():5-10. PubMed ID: 29241709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
    Bishop C; Krolewski DM; Eskow KL; Barnum CJ; Dupre KB; Deak T; Walker PD
    J Neurosci Res; 2009 May; 87(7):1645-58. PubMed ID: 19115412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.